EASL has launched a new educational activity called EASL Molecular Tumour Boards (EASL-MTB) comprised of a multidisciplinary panel of experts. The main purpose of this activity is to educate physicians and health allies on precision oncology based on molecular data in primary liver malignancies.
This EASL-MTB, held on 23 May 2023, discussed a clinical case of intrahepatic cholangiocarcinoma (CCA). CCA is a rare cancer type that develops in the biliary tree. Often silent and asymptomatic, these tumours are very aggressive, highly heterogeneous, chemoresistant, and their incidence is increasing worldwide. Due to the intrinsic tumour characteristics, efficacy of the current treatment options is compromised and CCA remains a highly lethal disease. The expert panel discussed the radiological and pathological aspects together with Target Enrichment Sequencing (TES) results and allocation of treatment.
You can address your questions through the chat function below.
A chat is available to post your questions and interact with your peers. Please note that the following content is considered inappropriate and will be deleted by the EASL Campus Team:
- foul language
- person attacks
- spam links
- sensitive information (personal info, phone numbers, etc.)
- links to executable files
Thank you for your understanding.
